Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Care Anywhere: The Journey Begins

The 'Care Anywhere' podcast series launches to explore the global healthcare workforce shortage crisis and the role of credentialing in enabling care delivery across borders. Hosted under EY's healthcare practice, the series examines systemic challenges reshaping how and where healthcare professionals are deployed. It aims to surface practical insights for industry leaders navigating workforce and credentialing complexity.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Lea Sims · Care Anywhere PodcastCgfns InternationalHealthcare CredentialingHealthcare Workforce
Share

Key takeaways

01

A new podcast series focused on global healthcare workforce shortages and credentialing challenges is launching.

02

The series is positioned to address how credentialing systems must evolve to support cross-border and flexible care delivery.

03

EY's healthcare expertise provides the backdrop for exploring structural and operational solutions to the workforce crisis.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In the inaugural episode of Care Anywhere: The Global Health Workforce Podcast, host Lea Sims, CMO of CGFNS International, Inc., introduces the organization's mission to address global healthcare workforce challenges. Joining the discussion are Dr. Peter Preziosi, President and CEO of CGFNS International, Inc., and Julia To Dutka, Chief of the CGFNS Global Health Workforce Development Institute, who explore the evolving landscape of healthcare, workforce shortages, and the need for innovation in credentialing and workforce development.

CGFNS: A Global Leader in Workforce Solutions

Dr. Preziosi describes CGFNS as a global health workforce solutions company with a focus on career mobility, credentialing, and workforce development. “We have a real opportunity here to lift up the health workforce all around the world to better prepare them for the major challenges,” he explains, highlighting CGFNS's pivotal role in shaping the future of global healthcare.

We have a real opportunity here to lift up the health workforce all around the world to better prepare them for the major challenges.
— Dr. Peter Preziosi, President and CEO of CGFNS International, Inc.

Julia To Dutka adds that CGFNS's strengths in assessment and certification, along with the creation of the Global Health Workforce Development Institute, position the organization to address healthcare challenges during a critical time.

Addressing Workforce Shortages and Collaboration

The conversation turns to the global workforce shortage, with Dr. Preziosi stressing that the issue is not just about numbers but about deploying healthcare workers more effectively. He notes that many countries face insufficiencies in skills and proper placement, and ministries of health and labor are looking for solutions.

Julia To Dutka emphasizes the importance of breaking down professional silos to improve collaboration. “Unless we can move in those directions, we're not going to get anywhere,” she remarks.

Unless we can move in those directions, we're not going to get anywhere.
— Julia To Dutka, Chief of the CGFNS Global Health Workforce Development Institute

Global Certification for Healthcare Workers

A significant focus for CGFNS is global certification. Julia To Dutka discusses the recent launch of the global certification exam for rehabilitation nurses, which sets a new standard in validating healthcare worker skills. “We now have a model we can apply to other high-need areas,” she says, underscoring the organization's commitment to workforce development.

With a focus on career mobility, certification, and global collaboration, CGFNS is well-positioned to address the complex challenges facing healthcare today and lead future innovations.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

LS
Lea Sims
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

LS
Lea Sims

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512